Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, has completed the acquisition of a phase 1 N,N-Dimethyltryptamine (“N,N-DMT”) study, the largest DMT study to date. The study provides key data relating to the company’s proprietary CYB004 substance with the potential to effectively treat anxiety disorders. “The phase 1 EBRX-101 study, now named CYB004-E, was acquired from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) FSE: 1XU1) through Cybin IRL Limited, Cybin’s wholly owned subsidiary… The adaptive, randomized, double-blinded, placebo-controlled, single-ascending-dose study produced notable results. According to the study, inhaled CYB004 showed an estimated 2,000% improved bioavailability compared with orally administered DMT and a 41% improved bioavailability compared with inhaled DMT. In addition, Cybin’s CYB004 demonstrated an approximately 300% longer duration of effect when compared with IV DMT as well as a rapid onset of effects and low variability equivalent to IV DMT,” explains a recent article. “The most precious commodity in drug development is time and acquiring this robust phase 1 study already underway potentially accelerates the CYB004 development program by approximately nine months,” said Cybin CEO Doug Drysdale.
To view the full article, visit https://ibn.fm/F6Yxy
About Cybin Inc.
Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.PsychedelicNewsWire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.PsychedelicNewsWire.com
415.949.5050 Office
[email protected]
PsychedelicNewsWire is part of the InvestorBrandNetwork.